The Rationalization of EAPs for Small Biotech
- Getting to Phase 3 – The story of WinSantTor
- When Innovation is not always a good thing
- Going from unfundable to a precommercial company in three months
- The difference of Right to Try and Compassionate Use
- Navigating the evolving Expanded Access Programs globally
- How Right to Try will disrupt Innovation for other biotechs